UTC’s Losses Mount in Bids to Delay Liquidia’s Rival Lung Drug

A federal judge in Delaware denied United Therapeutics Corp.’s latest bid to further delay the launch of a treatment that would compete with its blockbuster lung-disease drug Tyvaso.

Judge Richard G. Andrews rejected UTC’s motion to stay his order—and the amended final judgment that opened the door for approval of Liquidia Corp.'s Yutrepia—for the duration of UTC’s appeal, according to an opinion issued Wednesday in the US District Court for the District of Delaware.

“I agree with Liquidia that an invalid patent cannot give rise to an injunction,” Andrews wrote.

There’s no basis for UTC to claim it’d suffer irreparable ...